ATE448244T1 - Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung - Google Patents

Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung

Info

Publication number
ATE448244T1
ATE448244T1 AT00936995T AT00936995T ATE448244T1 AT E448244 T1 ATE448244 T1 AT E448244T1 AT 00936995 T AT00936995 T AT 00936995T AT 00936995 T AT00936995 T AT 00936995T AT E448244 T1 ATE448244 T1 AT E448244T1
Authority
AT
Austria
Prior art keywords
hiv
derivatives
nef
induce
protein
Prior art date
Application number
AT00936995T
Other languages
English (en)
Inventor
Jeannine Choppin
Villada Isabelle Bourgault
Jean-Gerard Guillet
Francine Connan
Estelle Ferries
Original Assignee
Inserm Transfert Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Transfert Sa filed Critical Inserm Transfert Sa
Application granted granted Critical
Publication of ATE448244T1 publication Critical patent/ATE448244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00936995T 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung ATE448244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907012A FR2794370B1 (fr) 1999-06-03 1999-06-03 Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
PCT/FR2000/001514 WO2000075181A1 (fr) 1999-06-03 2000-05-31 FRAGMENTS PROTEIQUES POLYEPITOPIQUES DE LA PROTEINE Nef DE HIV, LEUR OBTENTION ET LEURS UTILISATIONS NOTAMMENT EN VACCINATION

Publications (1)

Publication Number Publication Date
ATE448244T1 true ATE448244T1 (de) 2009-11-15

Family

ID=9546327

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00936995T ATE448244T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung
AT00938875T ATE554172T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00938875T ATE554172T1 (de) 1999-06-03 2000-05-31 Proteinfragmente die polyepitope der proteine e6 und e7 von hpv umfassen, deren herstellung und verwendung insbesondere zur impfung

Country Status (9)

Country Link
US (3) US6783763B1 (de)
EP (3) EP1183368B1 (de)
AT (2) ATE448244T1 (de)
AU (2) AU5229400A (de)
CA (2) CA2375602A1 (de)
DE (1) DE60043299D1 (de)
ES (2) ES2386803T3 (de)
FR (1) FR2794370B1 (de)
WO (2) WO2000075336A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
DK1276896T3 (da) * 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1213299A1 (de) * 2000-12-08 2002-06-12 Leids Universitair Medisch Centrum Immunogene epitopen des menschlichen Papillom-Virus und deren Anwendung
EP1355925A2 (de) * 2000-12-08 2003-10-29 Academisch Ziekenhuis Leiden Lange peptide mit 22-45 aminosäureresten, die antigenspezifische immunreaktionen induzieren und/oder fördern
FR2820425B1 (fr) * 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
BR0210252A (pt) * 2001-07-13 2004-09-14 Pepharm R & D Ltd Peptìdeos biologicamente ativos
CN1223602C (zh) 2001-07-13 2005-10-19 一泰医药研究（深圳）有限公司 序列号11的生物活性肽
SI1421200T1 (sl) * 2001-08-23 2007-04-30 Merck & Co Inc Poskusi PCR fluorescentnih multipleks HPV-jev z uporabo vec fluoroforov
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
JP4549858B2 (ja) 2002-10-17 2010-09-22 バイオリーダーズ コーポレイション ヒト・パピローマウイルスに対するワクチン用ベクターおよび同ベクターによって形質転換された微生物
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
KR101354740B1 (ko) 2004-04-28 2014-01-22 헤드워터스 헤비 오일, 엘엘씨 에뷸레이트 베드 하이드로프로세싱 방법 및 시스템 및기존의 에뷸레이트 베드 시스템을 개량하는 방법
US7517446B2 (en) * 2004-04-28 2009-04-14 Headwaters Heavy Oil, Llc Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
EP1819835B1 (de) 2004-12-08 2010-08-04 Gen-Probe Incorporated Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US20070037180A1 (en) * 2005-02-10 2007-02-15 Olle Nilsson Site-specific immunization in order to establish antibodies with specificity for the E7 oncoprotein of high-risk HPV's
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
CA3057039C (en) * 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2468763B1 (de) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
JP5267969B2 (ja) * 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
EP2276495B1 (de) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulierung einer immunantwort durch enantiomere von kationischen lipiden
US8586707B2 (en) * 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
KR101471043B1 (ko) * 2009-01-08 2014-12-09 주식회사 바이오리더스 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
EP2445927B1 (de) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidierte tumorassoziierte antigene und immuntherapiezusammensetzungen
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
WO2012116220A2 (en) 2011-02-24 2012-08-30 Qiagen Gaithersburg, Inc. Materials and methods for detection of hpv nucleic acid
WO2013039989A1 (en) 2011-09-12 2013-03-21 Pds Biotechnology Corporation Particluate vaccine formulations
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
CN103342738B (zh) * 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
WO2016005789A1 (en) * 2014-07-07 2016-01-14 Institut Pasteur Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus- associated cancer stages
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
SG11201811442UA (en) 2016-06-20 2019-01-30 Isa Pharmaceuticals B V Formulation of a peptide vaccine
CN108164587A (zh) * 2016-12-07 2018-06-15 中国医学科学院肿瘤医院 新的hpv抗原表位
KR102505534B1 (ko) 2017-03-02 2023-03-02 하이드로카본 테크놀로지 앤 이노베이션, 엘엘씨 오염 침전물이 적은 업그레이드된 에뷸레이티드 베드 반응기
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
WO2019145792A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
US12497569B2 (en) 2022-05-26 2025-12-16 Hydrocarbon Technology & Innovation, Llc Method and system for mixing catalyst precursor into heavy oil using a high boiling hydrocarbon diluent
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
EP0451550A3 (en) 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
ES2193133T3 (es) 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
AUPO390396A0 (en) * 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques

Also Published As

Publication number Publication date
US20080248044A1 (en) 2008-10-09
US6783763B1 (en) 2004-08-31
CA2375602A1 (fr) 2000-12-14
US7288258B2 (en) 2007-10-30
CA2375627A1 (en) 2000-12-14
DE60043299D1 (de) 2009-12-24
EP1181314B1 (de) 2009-11-11
AU5411000A (en) 2000-12-28
AU5229400A (en) 2000-12-28
EP2267132A2 (de) 2010-12-29
ES2386803T3 (es) 2012-08-31
WO2000075336A3 (fr) 2001-07-26
EP1181314B8 (de) 2010-02-17
ES2509901T3 (es) 2014-10-20
EP2267132A3 (de) 2011-04-20
FR2794370B1 (fr) 2003-10-17
EP2267132B1 (de) 2014-07-16
ATE554172T1 (de) 2012-05-15
US20050033025A1 (en) 2005-02-10
EP1183368A2 (de) 2002-03-06
EP1183368B1 (de) 2012-04-18
WO2000075181A1 (fr) 2000-12-14
EP1181314A1 (de) 2002-02-27
FR2794370A1 (fr) 2000-12-08
WO2000075336A2 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE448244T1 (de) Proteinfragmente die polyepitope des nef proteins von hiv umfassen, deren herstellung und verwendungen insbesondere zur impfung
Legler et al. Chemokines: chemistry, biochemistry and biological function
ES2199959T3 (es) Procedimiento mejorado para el replegamiento de proteinas.
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
KR930700143A (ko) B형 간염 백신
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
RU2401307C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFK2, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ПЕПТИДА, ЯВЛЯЮЩЕГОСЯ АНАЛОГОМ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ПЕПТИДА И РЕКОМБИНАНТНЫЙ ПЕПТИД, АНАЛОГ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, ОБЛАДАЮЩИЙ АПОПТОТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РАКОВЫМ КЛЕТКАМ
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
ATE208815T1 (de) Genetisches igfbp-5 rodierendes material
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
ATE351904T1 (de) Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen
JPS61225130A (ja) 鶏卵卵白システインの単離方法およびこれを含有するウイルス感染の処置剤
JPH02502825A (ja) 好中球活性化因子
DK35891A (da) Praktisk taget rent, antigenisk peptid eller protein med en epitop af haemophilus influenzae, dets fremstilling og anvendelse
CN110078793A (zh) 一种具有抗衰老和修复作用的多肽及其用途
CA2512515A1 (en) Super-antigen fusion proteins and the use thereof
BR9713540A (pt) Procedimento para a expressão do gene do vìrus da dengue
DE3751646D1 (de) Rekombinantes Produkt
BR0016289A (pt) Vìrus sentinela i do vìrus da hepatite
EP1749833A1 (de) Super-Antigene aus dem E2-Spike-Protein des SARS-Coronavirus
DE60234847D1 (de) N-desoxyribosyltransferase aus lactobacillus, entsprechende nukleinsäuren darauf und ihre verwendungen
AU772986B2 (en) Staphylococcal enterotoxin SEC-SER, expression vector and host cell, production method thereof, and manufacturing method of vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties